Skip to main content
Allo-HSCT in CR1 beneficial for elderly AML patients with unfavorable or intermediate-risk cytogenetics
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Allo-HSCT in CR1 beneficial for elderly AML patients with unfavorable or intermediate-risk cytogenetics
User login
Username
Password
Reset your password
Type
Lead
score
Edit Tags